Commentary on: “Focal cryosurgical ablation of the prostate: A single institute’s perspective”
Urologic Oncology Branch, National Cancer Institute, NIH, Building 10, Room 2W-5940, 10 Center Drive, MSC 1210, Bethesda, MD 2089s, USA
BMC Urology 2013, 13:39 doi:10.1186/1471-2490-13-39Published: 2 August 2013
The morbidity of whole gland treatment for prostate cancer is significant. Given the low risk of prostate cancer specific mortality for most men diagnosed with prostate cancer, alternative therapies such as sub-total or hemi-ablation of the prostate and focal ablation of prostate tumors are being investigated. The developing role of imaging for prostate tumors will dramatically change and likely improve the treatment morbidity for low risk prostate tumors. Commentary on: http://www.biomedcentral.com/1471-2490/13/2 webcite.